IP Verse

Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione - EP2797581B1

PatentPatent Analysis

EP2797581

AMGEN EUROPE
Application Number
EP12808662A
Filing Date
Dec 26, 2012
Status
Revoked
Aug 27, 2021
Grant Date
May 6, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2651400B2
EP3320902B1
EP2687213B1

Bibliography

The patent EP2797581B1 was granted to Amgen Europe on May 6, 2020 following the initial filing on Dec 26, 2012 under the application number EP12808662A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUFeb 8, 2021ADMISSIBLE
KRKAFeb 5, 2021ADMISSIBLE
GENERICS UKJan 19, 2021ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents